Lotus Pharmaceutical announced on Nov 24 that its acquisition of Alvogen US has been officially approved by the Department of Investment Review, Ministry of Economic Affairs (MOEA). As this approval was a critical regulatory prerequisite, Lotus expects to finalize the transaction by the end of 2024.

General Manager Petar Vazharov stated that this milestone significantly enhances Lotus’s scale and reinforces its position as a global leader in specialty pharmaceuticals. Following the closing, Lotus will integrate Alvogen US, a move expected to provide a substantial boost to the company’s presence in the U.S. market and its overall global R&D pipeline. The company is currently initiating internal procedures and public filings to ensure a seamless transition into 2025.

Resource: 美時收購Alvogen US，投審會准了，目標年底前完成交易